Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IRS1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IRS1 Full-Length / PTB Domain / PH Domain Protein (WT and Mutant e.g., G972R). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View IRS1 Products |
| Gene Delivery | IRS1 Promise-ORF / Lentivirus. Full-length ORF with native codon optimization for stable cell lines. | View IRS1 Products |
| Benchmark Ab | Anti-IRS1 Recombinant Antibody (Pan-specific). Recombinant positive control for Western/IP/ELISA. | View IRS1 Products |
| Validator | IRS1 siRNA Set (3 targets + scramble control). For knockdown verification and specificity controls. | View IRS1 Products |
| Upstream Regulator | INSR (Insulin Receptor). Tyrosine kinase partner for activation assays. | View INSR Products |
| Upstream Regulator | IGF1R. Upstream receptor kinase driving IRS1 phosphorylation. | View IGF1R Products |
| Parallel Isoform | IRS2. Critical for selectivity profiling (avoid off-target metabolic effects). | View IRS2 Products |
| Downstream Effector | PIK3CA (p110α). PI3K pathway component for survival signaling. | View PIK3CA Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Targeting / PROTAC Design | High-purity recombinant domains (PH: 1-115aa; PTB: 158-267aa) with precise theoretical MW for SPR/BLI binding assays. Distinct tags (GST vs His) for pull-down flexibility. |
| Mutant Profiling in Insulin Resistance | Specific disease-linked mutant proteins (e.g., G972R) strictly sequence verified. |
| Lack of Controls | Recombinant Benchmark Antibodies included for reproducible western/ELISA readouts. |
| False Positives in Phenotypic Screens | Validated siRNA included for specificity checks and pathway isolation. |
| Phosphorylation site specificity (pY608, pY628, pY658) | Phospho-mimetic (Glu) and phospho-deficient (Phe) mutants available; Sequence Verified by Mass Spec. |
| Isoform selectivity (IRS1 vs IRS2 vs IRS3 vs IRS4) | Ortholog panel with <70% homology regions purified to >95% for differential binding assays. |
| Intracellular delivery confirmation | Lentivirus particles (titer >10^8 TU/ml) for stable overexpression in HepG2/3T3-L1 cell lines. |
| Competitive compound screening | High-concentration protein (5-10 mg/ml) available for NMR/SPR fragment screening. |
Live IRS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IRS1 therapeutics is evolving rapidly. Traditionally considered "undruggable" due to its nature as an intracellular adaptor protein lacking enzymatic activity, major players are shifting focus from conventional small molecules to novel modalities like RNAi, ASOs, and PROTACs. As first-generation PTP1B inhibitors faced liability issues due to IRS2 compensatory activation, the next wave of R&D is targeting IRS1-specific protein-protein interactions (PPIs) and targeted protein degradation (TPD) approaches to circumvent feedback activation. Oncology applications are emerging where IRS1 inhibition may break PI3K-driven cancer metabolic adaptation, while in metabolic disease the goal is to reverse insulin resistance without triggering IRS2-mediated side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNAi / ASO | Metabolic Biotech Innovators | Type 2 Diabetes, Obesity | Knockdown Validation (Need validated siRNA/Lentivirus) |
| Small Molecule PPI Inhibitors | Novo Nordisk, Eli Lilly, Academic & Pharma Consortia | Type 2 Diabetes, Insulin Resistance, Cancer | PTB Domain Binding Assay (Need phospho-mimetic Y608E mutant) and HTS (Need WT and Mutant proteins) |
| Peptide/Miniprotein | Structure-based biotechs | Metabolic Syndrome | Competition SPR with full-length IRS1 vs truncated domains |
| PROTAC / Molecular Glue | E3 ligase platform companies; Emerging Oncology Startups | Cancer (Breast, Prostate, Refractory Solid Tumors) | Ternary Complex Assays & Cell-based degradation assay (Need high-purity recombinant domains and Lentivirus stable lines) |
| Allosteric Modulators | Academic drug discovery centers | NAFLD/NASH | Conformational stability assay (Need high-purity PH domain) |
Molecular Differentiation Strategy & Related Targets
Differentiation Factors:
- Affinity & Specificity: For PROTAC ligands or PPI blockers, precise binding to PTB or PH domain with >100-fold selectivity over IRS2 is required. Use TarMart's IRS1/IRS2 domain pairs for counter-screening.
- Delivery: For RNAi/ASO strategies, hepatic delivery (GalNAc/LNP) is critical; validate with TarMart Lentivirus in HepG2 cells.
- Mechanism: PROTACs require ternary complex formation; use TarMart's full-length IRS1 and VHL/EloBC complex for in vitro pulldown.
Related Targets for Cross-Selling:
- IGF1R: Upstream receptor; combine with IRS1 for resistance studies.
- PTPN1 (PTP1B): Interplay with IRS1 phosphorylation; dual modulation may improve metabolic control.
- PIK3R1 (p85α): Interaction with IRS1 YXXM motifs; selective blockade avoids direct PI3K toxicity.
TarMart provides all necessary reagents: recombinant proteins (WT, mutant, phospho-mimetic), Lentivirus, siRNA, and benchmark antibodies, enabling a complete IRS1 drug discovery workflow.